Kitov Pharmaceuticals Hldgs L Sponsored ADR (KTOV)

[midastouch017]

Conclusions
[From the SA in depth article]

KTOV shares have a significant short and long-term upside because of the upcoming launch of Consensi and planned clinical trials with drug candidates NT-219 and CM-24
As a result of Consensi's commercialization plan, the Company expects to receive aggregate milestone and royalty revenues of between $28 million and $36 million from 2020 through 2022.
The company plans to begin NT-219 clinical trials in 1H 2020 and CM-24 combination trials with Bristol Myers Squibb blockbuster drug Opdivo in 2H 2020.
Revenues derived from Consensi's sales will help fund NT-219 and CM-24 drug candidates thus minimizing dilution going forward
The potential for NT-219 to be effective across several oncology therapies is what makes it a potential blockbuster drug. A great example is NT-219’s potential to convert non-responders to responders with Merck's Keytruda. Positive results in early clinical trails could result in significant partnerships with large pharma.
CM-24 has the potential to treat recurrent and advanced stage cancers including ovarian, colorectal, melanoma, lung, bladder and gastric cancers. The company's Phase I/II trial design could result in a strong display of the drug's efficacy to the benefit of patients and their families and potential lucrative partnerships
I recommend that those interested in investing in KTOV shares to read carefully the risks and uncertainties of doing so as detailed in the most recent company filings with the SEC.

Disclosure: I am/we are long KTOV.